Chemours Company (The) (NYSE:CC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, July 12th.

According to Zacks, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington. “

Other research analysts have also recently issued research reports about the stock. Jefferies Group LLC reiterated a “buy” rating and set a $48.00 price target on shares of Chemours Company (The) in a research note on Friday, June 16th. ValuEngine upgraded shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Citigroup Inc. lifted their price target on shares of Chemours Company (The) from $62.00 to $63.00 and gave the stock a “buy” rating in a research note on Monday, April 17th. BidaskClub downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Finally, J P Morgan Chase & Co upgraded shares of Chemours Company (The) from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $39.00 to $50.00 in a research report on Friday, May 12th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $46.25.

Shares of Chemours Company (NYSE:CC) traded down 5.16% during midday trading on Wednesday, reaching $47.20. The company had a trading volume of 3,850,249 shares. The firm has a market capitalization of $8.73 billion, a P/E ratio of 30.87 and a beta of 3.63. Chemours Company has a one year low of $9.12 and a one year high of $50.04. The company has a 50 day moving average price of $42.16 and a 200-day moving average price of $37.26.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.27 EPS. On average, analysts anticipate that Chemours Company will post $3.51 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/08/zacks-investment-research-downgrades-chemours-company-the-cc-to-hold-updated-updated-updated.html.

In other Chemours Company (The) news, insider Paul Kirsch sold 19,036 shares of Chemours Company (The) stock in a transaction on Monday, June 5th. The shares were sold at an average price of $41.42, for a total value of $788,471.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Erich Parker sold 4,908 shares of Chemours Company (The) stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Financial Architects Inc boosted its position in Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after buying an additional 2,719 shares in the last quarter. Ropes Wealth Advisors LLC boosted its position in Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock worth $119,000 after buying an additional 1,400 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Chemours Company (The) by 2,138.8% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after buying an additional 2,973 shares in the last quarter. Schroder Investment Management Group purchased a new position in Chemours Company (The) during the first quarter worth approximately $156,000. Finally, Cypress Capital Management LLC WY boosted its position in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock worth $162,000 after buying an additional 80 shares in the last quarter. 75.21% of the stock is owned by institutional investors and hedge funds.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Get a free copy of the Zacks research report on Chemours Company (The) (CC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.